We hypothesize that CTCL, like other cancers, harbors clinically actionable genetic drivers of disease progression and propose a comprehensive genomics approach to identify these mutations. To find these mutations, we will utilize my lab’s expertise in genomics to genetically analyze a large cohort of CTCL patients (>420 cases) from Northwestern’s robust clinically annotated biobank. Specifically, our aims are to perform 1) whole genome sequencing of paired samples pre- and post disease progression and 2) targeted resequencing of a cohort of unpaired Stage I, II, III, and IV CTCLs.
|Effective start/end date||7/1/16 → 10/31/17|
- Leukemia Research Foundation (AGREEMENT 6/13/16)